
Sign up to save your podcasts
Or


Alexion's top-brass has hit the exits amid an investigation into sales practices, and Ophthotech's future is in jeopardy following a high-profile phase 3 failure.
By The Motley FoolAlexion's top-brass has hit the exits amid an investigation into sales practices, and Ophthotech's future is in jeopardy following a high-profile phase 3 failure.